Charles River Laboratories International Inc$CRL has seen significant movements recently with notable parties taking action.
JPMorgan Chase& Co.,
Confluence Investment Management LLC, and the
National Bank of Canada FI have all increased their stake in the company. However, there's been an opposite trend with
Barclays PLC,
Mackenzie Financial Corp, &
Integral Health Asset Management LLC reducing their holdings.
Charles River Laboratories exceeded analyst EPS estimates and witnessed an increase in
short interest. The company’s stocks exhibited strong trading performance on specific days, but underperformed compared to its competitors on others. Following a guidance cut and
planned divestitures, there is attention around its evaluation. The company has faced pressure from
biotech R&D spending headwinds, drawing mixed reactions from investors. Additionally, there's been a
stock buyback planned of US1$ billion, and insider-trading activity has also been highlighted.
Charles River Laboratories International CRL News Analytics from Tue, 23 Sep 2025 07:00:00 GMT to Sat, 21 Mar 2026 09:38:26 GMT -
Rating 2
- Innovation -2
- Information 6
